Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
D 72.14 -0.15% -0.11
LGND closed down 0.15 percent on Monday, March 18, 2024, on 1.2 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -0.15%
Oversold Stochastic Weakness -0.15%
50 DMA Resistance Bearish -2.21%
Calm After Storm Range Contraction -2.21%
Outside Day Range Expansion -2.21%
Oversold Stochastic Weakness -2.21%

   Recent Intraday Alerts

Alert Time
Up 1% about 9 hours ago
60 Minute Opening Range Breakout about 11 hours ago
Down 2 % about 12 hours ago
Fell Below Previous Day's Low about 12 hours ago
Down 1% about 12 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ligand Pharmaceuticals Incorporated Description

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Pain Alzheimer's Disease Organic Compounds Chemical Compounds Kidney Disease Multiple Myeloma Sarcoma Myelodysplastic Syndrome Osteoporosis Chronic Lymphocytic Leukemia Lymphocytic Leukemia Chloroarenes Clinical Trial Product Seizure Phenols Thrombocytopenia Carboxylic Acids Clopidogrel Immune Thrombocytopenic Purpura

Is LGND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 94.57
52 Week Low 49.25
Average Volume 140,306
200-Day Moving Average 66.74
50-Day Moving Average 74.18
20-Day Moving Average 75.35
10-Day Moving Average 75.60
Average True Range 3.73
RSI (14) 44.75
ADX 17.98
+DI 24.15
-DI 23.21
Chandelier Exit (Long, 3 ATRs) 83.39
Chandelier Exit (Short, 3 ATRs) 81.29
Upper Bollinger Bands 84.14
Lower Bollinger Band 66.56
Percent B (%b) 0.32
BandWidth 23.32
MACD Line -0.20
MACD Signal Line 0.64
MACD Histogram -0.8389
Fundamentals Value
Market Cap 1.26 Billion
Num Shares 17.4 Million
EPS 1.14
Price-to-Earnings (P/E) Ratio 63.28
Price-to-Sales 8.61
Price-to-Book 1.98
PEG Ratio 1.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.45
Resistance 3 (R3) 77.36 75.51 76.57
Resistance 2 (R2) 75.51 74.15 75.55 76.27
Resistance 1 (R1) 73.82 73.32 74.67 73.91 75.98
Pivot Point 71.97 71.97 72.39 72.01 71.97
Support 1 (S1) 70.28 70.61 71.12 70.37 68.30
Support 2 (S2) 68.43 69.78 68.47 68.01
Support 3 (S3) 66.74 68.43 67.71
Support 4 (S4) 66.83